- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- ABBV-6628, SYFOVRE
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Carmel, Indiana • Reno, Nevada • Abilene, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- RO7669330, Syfovre™, Izervay™
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more
- Conditions
- Geographic Atrophy
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 34
- States / cities
- Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-2, Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Oxnard, California • Austin, Texas + 2 more